Skip to main content
. Author manuscript; available in PMC: 2008 Dec 17.
Published in final edited form as: Vaccine. 2007 Nov 5;25(52):8687–8701. doi: 10.1016/j.vaccine.2007.10.030

Figure 3.

Figure 3

Antigen-specific humoral immune responses. A and B, Antibody responses against HIV-1 gag in mucosal samples. C, Serum neutralizing responses against adenovirus. ELISA plates were coated with HIV-1 gag and 1:2 dilutions of saliva (A) and vaginal washes (B) were reacted. After reaction with secondary anti-IgA HRP conjugate and subsequent colorimetric substrate, data were presented as the O.D. values measured at 450 nm. Error bars indicate standard deviations of three measurements taken per time point. Statistical significance was verified for each time point against the background using a Student’s paired t test and a p value < 0.05. C) Serum samples take at the indicated times were incubated with Ad5 expressing luciferase for 1 hour at 37°C prior to addition to 293 cells at 250 viral particles per cel. 24 hours later, luciferase activity was measured and gene delivery was compared to untreated Ad5 vector. Data is expressed as geometric mean titers that reduced Ad luciferase activity 50%.